ChromaDex (CDXC) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ChromaDex Corporation Reports First Quarter 2020 Financial Results
May 11, 2020 4:01 PM EDTFirst Quarter 2020 Highlights vs. First Quarter 2019
Strong growth in net sales to $14.3 million, higher gross margins, and significantly improved marketing efficiency year-over-year. Tru Niagen net sales of $11.1 million, a 50% increase year-over-year. Net loss was ($5.9) million or ($0.10) per share, an improvement of $0.05 per share year over year. Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of ($0.3) million, a $2.4 million improvement year-over-year. Launched Tru Niagen online in Australia with distribution partner, Matakana Health Limited, and online through... More